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Abstract
Background: In 2011, Royston et al. described technical details of a two-arm, multi-stage (TAMS) design. The design
enables a trial to be stopped part-way through recruitment if the accumulating data suggests a lack of beneﬁt of the
experimental arm. Such interim decisions can be made using data on an available ‘intermediate’ outcome. At the
conclusion of the trial, the deﬁnitive outcome is analyzed. Typical intermediate and deﬁnitive outcomes in cancer
might be progression-free and overall survival, respectively. In TAMS designs, the stopping rule applied at the interim
stage(s) aﬀects the sampling distribution of the treatment eﬀect estimator, potentially inducing bias that needs
addressing.
Methods: We quantiﬁed the bias in the treatment eﬀect estimator in TAMS trials according to the size of the
treatment eﬀect and for diﬀerent designs. We also retrospectively ‘redesigned’ completed cancer trials as TAMS trials
and used the bootstrap to quantify bias.
Results: In trials in which the experimental treatment is better than the control and which continue to their planned
end, the bias in the estimate of treatment eﬀect is small and of no practical importance. In trials stopped for lack of
beneﬁt at an interim stage, the treatment eﬀect estimate is biased at the time of interim assessment. This bias is
markedly reduced by further patient follow-up and reanalysis at the planned ‘end’ of the trial.
Conclusions: Provided that all patients in a TAMS trial are followed up to the planned end of the trial, the bias in the
estimated treatment eﬀect is of no practical importance. Bias correction is then unnecessary.
Background
The two-arm, multi-stage (TAMS) trial design described
by Royston et al. [1] provides a framework for eﬃciently
evaluating an experimental treatment regimen against
a control group, by using an intermediate outcome to
potentially cease the trial for lack of beneﬁt at an early
stage. Choosing appropriate and valid intermediate (I) and
deﬁnitive (D) outcomes is key to the success of a TAMS
trial, for which Royston et al. [1] provides guidance. In
this framework, we assume that both the intermediate
and ﬁnal outcomes are time-to-event outcomes. The basic
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assumptions are that I occurs no later than D, more fre-
quently than D and is on the causal pathway to D. If
the null hypothesis is true for I, it must also hold for
D. In the absence of an obvious choice for I, a ratio-
nal choice of I might be D itself earlier in time. In this
instance, of course, I does not occur more frequently than
D. The TAMS design framework can be well suited to can-
cer trials. In the cancer context, typical intermediate and
deﬁnitive outcomes might be progression-free survival
(PFS) and overall survival (OS), respectively. Information
on PFS is usually available sooner in a study, and in most
cancer sites, the treatment eﬀect on PFS is usually highly
positively correlated with that on OS [1].
It is well known that stopping a trial early, for exam-
ple in sequential and group sequential designs, may yield
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biased estimates of the treatment eﬀect (Piantadosi [2],
pp. 183, 387). By the ‘treatment eﬀect’ we mean the diﬀer-
ence on some suitable scale between the experimental and
control arms; typically, for time-to-event data this will be
the (log) hazard ratio between the survival distributions
under proportional hazards (PH). When a trial is stopped
early because accumulating evidence favors the alterna-
tive hypothesis, the maximum partial likelihood estimate
(MPLE) of the treatment eﬀect – in the context of the Cox
PH model – is biased in the direction of the alternative
hypothesis. The earlier a trial is stopped, the larger the
potential bias [2]. Although the TAMS design framework
can help (and is helping [3]) to expedite the discovery
and evaluation of new and eﬀective treatments, concerns
have been raised about possible bias in the ﬁnal treatment
eﬀect estimate induced by this approach, for example,
hazard ratios (HRD) on OS for trials with time-to-event
outcomes.
In a TAMS trial, recruitment is halted at one of the
interim stages if there is insuﬃcient evidence in favor
of the alternative hypothesis. Emerson [4] showed that
applying any stopping rule aﬀects the sampling distribu-
tion of the MPLE of the treatment eﬀect (see Figure 3
in [4]) and consequently induces a potential bias. The
distribution of test statistics and their P values are simi-
larly aﬀected by such rules. However, hypothesis testing is
not the focus of the present paper as it has been already
addressed in [1]. Bias is present in the estimated treat-
ment eﬀect whether or not a trial is stopped for lack
of beneﬁt. However, bias in treatment eﬀect estimates
in trials passing all interim lack-of-beneﬁt assessments is
more important than that in stopped trials, since such
experimental treatments are much more likely to be con-
sidered worthy of further study or adoption into clinical
practice.
Regardless of an interim decision on whether to stop or
not, it is still important to estimate the treatment eﬀect
using all available data. Royston et al.’s [5] proposal to ter-
minate recruitment of new patients if the experimental
arm fails to show evidence of beneﬁt, while at the same
time continuing to follow up all recruited patients, was
designed to make TAMS trials cost eﬃcient but also to
mitigate possible bias. However, the precise magnitude of
the bias present in the ﬁnal treatment eﬀect estimate has
not been rigorously explored. In this paper, we investi-
gate the bias in the estimates of treatment eﬀects resulting
from a TAMS design. We also deﬁne the ‘selection bias’ in
estimated hazard ratios and empirically quantify its likely
magnitude in TAMS trials through simulation studies
and bootstrap-based reanalyses of four completed cancer
trials.
The structure of the paper is as follows. In the Meth-
ods section, we ﬁrst outline how a TAMS trial is
speciﬁed, noting the required design parameters and
assumptions. Next, we discuss the ‘selection’ bias induced
in TAMS trials by the use of lack-of-beneﬁt stopping
guidelines. For simplicity, we discuss this issue in a two-
stage TAMS setting. We describe our simulation study
intended to explore the magnitude of the bias. The sim-
ulation study is carried out in a three-stage TAMS set-
ting. In this section, we also introduce four real trials
and ‘redesign’ them as if they were TAMS trials. In the
Results, we present simulation results. We also show the
results of our bootstrap reanalyses of the example tri-
als in an empirical assessment of bias at the deﬁnitive
analysis of the treatment eﬀect. This is followed by a
discussion.
Methods
Speciﬁcation of a TAMS design
In a TAMS trial, we compare one experimental arm, E,
with a control arm, C. A TAMS design has s ≥ 2 stages.
The ﬁrst s − 1 stages assess lack of beneﬁt by compar-
ing E with C on an intermediate outcome, I. The sth stage
compares E with C for eﬃcacy on the deﬁnitive outcome,
D. Let HRI be the underlying hazard ratio for comparing
E with C on I, and HRD be the underlying hazard ratio
comparing E with C on D.
We assume that proportional hazards hold between the
treatment arms, and also that the times to event are expo-
nentially distributed for both I and D outcomes, with
control-arm hazard rates of λI and λD, respectively.
The null and alternative hypotheses for a TAMS design
are:
H0 at stages 1 to s − 1 : HRI = HR0I
H1 at stages 1 to s − 1 : HRI = HR1I
H0 at stage s : HRD = HR0D
H1 at stage s : HRD = HR1D
The primary null and alternative hypotheses, H0 (stage s)
and H1 (stage s), concern HRD, with the hypotheses on I
playing a subsidiary role. However, we require design val-
ues for all the hypotheses. In practice, HR0I and HR0D are
almost always taken as 1. In cancer trials, HR1D = 0.75 is a
common choice.
Taking HR1I = HR1D is a conservative option; the design
allows for the possibility thatHR1I < HR1D. For example, in
cancer, if I is the earlier of progression or death and D is
death, it may be realistic and eﬃcient to take, say, HR1D =
0.75 and HR1I = 0.7.
By deﬁnition, if E is better than C then HRI < HR0I and
HRD < HR0D. Let ̂i (i < s) be the estimated hazard ratio
comparing EwithC on outcome I for all patients recruited
up to and including stage i, and ̂s be the hazard ratio
comparing E with C on D for all patients at stage s (that is,
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at the time of the analysis of the deﬁnitive outcome). The
design is speciﬁed as follows:
Applies to all stages:
1. Deﬁne the hazard rates λI and λD, or equivalently,
the median times to event.
2. Deﬁne hazard ratios HR0I , HR1I , HR0D and HR1D.
Usually, HR0I = HR0D = 1.
3. Deﬁne the allocation ratio, A, that is the number of
patients allocated to E for every patient allocated to
C. A = 1 represents equal allocation; with A < 1
relatively fewer patients are allocated to E, and with
A > 1, relatively more patients are allocated to E.
For stages 1 to s − 1:
1. For stage i, deﬁne a one-sided signiﬁcance level αi
and power ωi. The motivation for one-sided tests is
that we are interested only in rejecting the null
hypothesis in the direction of beneﬁt of E over C, not
harm. We also specify ri, the expected total patient
accrual rate per unit time.
2. From these inputs, the nstage software [6] reports
ei, the cumulative number of events to be observed in
the control arm during stages 1 through i ; ni, the
number of patients to be entered in the control arm
during stage i ; Ani, the corresponding number of
patients in the experimental arm; ti, the approximate
(calendar) time, ti, of the end of stage i, under the
design assumptions; and a critical value, δi, for
rejecting H0 : HRI = HR0I .
3. If ̂i ≥ δi, the null hypothesis of HRI = HR0I cannot
be rejected at the αi level, and the trial is stopped for
lack of beneﬁt of E over C. Otherwise, ̂i < δi,
suggesting some degree of beneﬁt of E, and
recruitment continues to the next stage.
Stage s:
The same principles apply to stage s as to stages 1 to
s − 1. Here, es is the required number of control arm
events for the D outcome, cumulative over all stages. We
would typically recommend a one-sided signiﬁcance level
of αs = 0.025 at stage s, corresponding to a conventional
two-sided 0.05 level.
If the treatment comparison survives all of the s − 1
tests at step 3 above, the trial proceeds to the ﬁnal stage,
otherwise recruitment is terminated early. Mathemati-
cal details of the sample size calculations are given in
Section Methods of Royston et al. [1].
Interim selection on a deﬁnitive outcome
Here we consider the bias induced in the estimated treat-
ment eﬀect in a two-stage TAMS design with I = D.
A lack-of-beneﬁt stopping rule is applied at the ﬁrst
(interim) stage. If the treatment comparison shows some
evidence of beneﬁt of the experimental arm, recruitment
continues and the deﬁnitive analysis is performed at a later
second stage. Otherwise, recruitment is terminated.
Let θD be the underlying log hazard ratio (log HR) com-
paring the experimental treatment with control.We deﬁne
θD such that θD < 0 denotes a true advantage of the exper-
imental treatment over control. Let θ̂D be the MPLE of θD.
In the absence of stopping rules, θ̂D is asymptotically unbi-
ased and approximately normally distributed in repeated
realizations of the trial ([7], p. 40). No bias enters, and so:
E
[
θˆD
]
= θD (1)
over repeated realizations of the trial.
Let θˆD be the estimated logHR for the data accumulated
at the ﬁrst stage (lack-of-beneﬁt analysis). Recruitment
stops if θˆD ≥ log(δ) and continues to the ﬁnal stage if
θˆD < log(δ). The threshold δ is predeﬁned according to a
designated signiﬁcance level and power. We have:
E
[
θˆD|θˆD < log(δ)
]
= θD − B1 (2)
E[ θˆD|θˆD  log(δ)]= θD + B2 (3)
where B1,B2 > 0 and are functions of θD. B1 and B2 may
be termed the selection bias [8] in θˆD in the two scenarios.
Expressions 2 and 3 state that under the PH assump-
tion θˆD is biased downwards by B1 and upwards by B2 in
continuing and stopped trials, respectively.
As an illustration, Figure 1 shows hypothetical sampling
distributions (densities) of θˆD at the ﬁrst stage for treat-
ments with θD negative, zero or positive. The vertical line
denotes a typical lack-of-beneﬁt threshold, log(δ) < 0.
The probability of passing the lack-of-beneﬁt threshold,
Figure 1 Sampling distribution of θˆD, that is, estimated log
hazard ratios, which are normally distributed, under diﬀerent
underlying eﬀects, θD. δ is the predeﬁned threshold.
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that is Pr
[
θˆD < log(δ)
]
, is the area under the appropriate
density to the left of δ. Trials of the treatment for which
θD < 0 (long-dashed line) have the largest chance of pass-
ing, and those for which θD > 0 (short-dashed line) have
the largest chance of stopping.
Selection bias B1 among ‘passed trials’ is the largest for
the treatment with θD > 0 and smallest for that with θD <
0. Conversely, selection bias B2 among ‘stopped trials’ is
the largest for the treatment with θD > 0 (dotted line) and
smallest for that with θD < 0 (dashed line).
Interim selection on an intermediate outcome
We now consider the more complex scenario where we
use a diﬀerent outcome I at the interim stage. In Royston
et al.’s [1] TAMS design it was proposed to cease/continue
accrual according to the value of an intermediate outcome
measure that is correlated with the deﬁnitive outcome
measure. An example is selection on the basis of PFS log
HRs but ultimately estimating the OS log HR. Now let
θˆD and θˆI be treatment eﬀect estimates on the D and I
outcomes, respectively, at the interim stage. The selection
bias in θˆD given that θˆI passed the predeﬁned threshold
log(δI) could be expressed as:
E
[
θˆD|θˆI < log (δI)
]
= θD − B3 (4)
for some B3 that depends on the underlying values
θD, θI and their correlation, ρθI ,θD . To illustrate this we
assume, as in Royston et al. [1], that θˆI and θˆD follow
a bivariate normal distribution with correlation ρθI ,θD .
Figure 2 shows 1,000 log hazard ratio pairs, (θˆI , θˆD), sim-
ulated from a bivariate normal distribution with mean
(log(0.8), log(0.8)) and a correlation coeﬃcient of 0.8.
Figure 2 Log hazard ratio pairs of (PFS, OS) simulated from a
bivariate normal distribution with mean (log(0.8), log(0.8)) and a
correlation coeﬃcient of 0.8. δI is the predeﬁned threshold. Blue
circles and red crosses represent selected and dropped trials,
respectively. OS, overall survival, PFS, progress-free survival.
Dots represent values of (θˆI , θˆD) in simulated trials in
which θˆI < δI . Because θˆI and θˆD are correlated, it is
clear that the mean of θˆD in trials that either continue
(θˆI < log(δI)) or are stopped (θˆI ≥ log(δI)) is biased with
respect to θD. In this example, the selection bias of the
‘stopped’ trials is larger than that of the ‘continuing’ trials,
since the square is closer to the circle than the triangle is
to the circle.
Simulation study
We conducted simulation studies to quantify the impact
of various stopping rules on the estimates of the θD,
that is log(HRD), in three-stage TAMS designs with two
interim analyses. We considered bias in two situations: (i)
simulated trials with an underlying hazard ratio close to
the null hypothesis, which are likely to be stopped at the
ﬁrst of the two intermediate stages due to apparent lack
of eﬃcacy; (ii) simulated trials with an underlying hazard
ratio close to the alternative hypothesis, which are more
likely to pass both intermediate stages to reach the ﬁnal
stage (analysis of theD outcome). To ﬁx ideas, we took the
D outcome as OS and the I outcome (used for selection)
as either OS or PFS. We denote the OS hazard ratio and
PFS hazard ratio as HRD and HRI , respectively. When the
I outcome was PFS, we generated correlated PFS and OS
times to event according to the method of Royston et al.
[1].
Design parameter values were based on the
GOG182/ICON5 trial in advanced ovarian cancer [9].
We assumed the median time-to-event for OS and PFS
outcomes to be 2 years and 1 year, respectively. (When
I=D, we assumed the median time-to-event to be 1 year.)
For sample size calculations, we chose the target hazard
ratio to be 0.75 for eﬃcacy and 1.0 for ineﬃcacy on both
outcome measures at all stages. Note that when I = D,
TAMS designs allow the target hazard ratio(s) for eﬃ-
cacy at intermediate stages to be diﬀerent (for example,
more extreme) than the target hazard ratio at the ﬁnal
stage. Such designs would be even more eﬃcient, but
we adopted the conservative option of taking all target
hazard ratios for eﬃcacy to be the same across stages.
We considered two TAMS designs (1 and 2) deﬁned by
diﬀerent sets of signiﬁcance levels (α1,α2,α3) at the three
stages. We took (α1,α2,α3) = (0.5, 0.25, 0.025) in Design
1 and (0.2, 0.1, 0.025) in Design 2. The interim analyses in
Design 1 take place earlier than those in Design 2. As sug-
gested by Royston et al. [1], we designated a stage-speciﬁc
power (ω1,ω2,ω3) = (0.95, 0.95, 0.90) in both designs.
Table 1 gives details of the design parameters. Calcula-
tions for Table 1 were done in Stata using the program
nstage [6].
When generating simulated times to event, we applied
each of four underlying hazard ratios: 1.1 and 1.0, to repre-
sent trials with an ineﬀective experimental treatment, and
Choodari-Oskooei et al. Trials 2013, 14:23 Page 5 of 15
http://www.trialsjournal.com/content/14/1/23
Table 1 Design parameters for two three-stage TAMSa trials
I and D outcomes: OSb I outcomes: PFSc; D outcomes: OSb
Design Stage αid ωie ri f δig eih ti i Ni j HR1k eih ti i Ni j HR1k
1 1 0.50 0.95 250 1.00 73 1.53 382 0.75 73 1.53 382 0.75
2 0.25 0.95 250 0.92 140 2.62 566 0.75 140 2.62 566 0.75
3 0.025 0.90 250 0.84 262 3.40 851 0.75 264 4.36 1091 0.75
2 1 0.2 0.95 250 0.91 159 2.45 612 0.75 159 2.45 612 0.75
2 0.1 0.95 250 0.89 217 3.00 750 0.75 217 3.00 750 0.75
3 0.025 0.90 250 0.84 262 3.40 851 0.75 264 4.36 1091 0.75
aTwo-armmulti-stage;
boverall survival;
cprogression-free survival;
dnominal signiﬁcance level at stage i;
enominal power at stage i;
frate of patient accrual per unit time during stage i;
gpredeﬁned threshold;
hcumulative number of control arm events required at end of stage i;
iduration (in time units) up to the end of stage i;
jcumulative number of patients accrued to control arm by end of stage i;
ktarget hazard ratio underH1 , the target hazard ratio for ineﬃcacyHR0 is 1 in all scenarios.
0.88 and 0.75, to represent trials with an eﬀective exper-
imental treatment. The ﬁrst two represent situation (i),
whereas the latter two represent situation (ii) as explained
above. In our simulations, 5,000 trials were replicated in
each experimental condition. For trials which stopped at
stage 1, we computed the mean of estimated OS log haz-
ard ratios, that is log(HRD), at that stage. For trials that
reach the ﬁnal stage, log(HRD) is computed at that stage.
In all scenarios, we report the results on the hazard ratio
scale. To provide an estimate of spread, we also present
the 2.5th and 97.5th centiles of the estimated OS hazard
ratios. Aside from hazard ratios, we also report the abso-
lute value (size) of percentage bias which is deﬁned as:
% Bias = 100× (EstimatedHR − UnderlyingHR)UnderlyingHR (5)
Data were simulated with staggered patient entry at
a uniform accrual rate of 250 individuals per year.
Equal numbers of patients were allocated to control and
experimental arms in all stages. We also carried out simi-
lar simulations with target hazard ratios for eﬃcacy of 0.85
instead of 0.75, requiring larger numbers of I andD events
and generally longer timelines.
Bootstrap reanalysis
Trials used as examples
To evaluate selection bias in the estimated treatment
eﬀects, we also ‘reanalyzed’ the data from four MRC-
coordinated cancer trials as though the trials were run
as two-stage TAMS designs (that is one interim analysis).
The selected trials comprise two in advanced renal can-
cer (RE01 [10], RE04 [11]) and two in advanced ovarian
cancer (ICON3 [12], ICON4 [13]). All except for RE04
were also reanalyzed from a methodological perspective
by Barthel et al. [14]. ICON3 and RE04 were ‘unsuccessful’
in that no conventionally statistically signiﬁcant treatment
eﬀect was found. ICON4 and RE01 were conventionally
‘successful’ and demonstrated clear evidence of improve-
ment in survival due to the experimental therapy. Some
details of the trial results are given in Table 2.
Table 2 The estimated PFS and OS hazard ratios at the end of the four example trials
Trial Control arm Experimental arm Hazard ratio (95% CI)
Treatment Na eb Treatment Na eb PFSc P value OSd P value
ICON3 Carbo/CAP 1350 827 Carbo, TAX 698 431 0.93(0.83–1.03) 0.15 0.97(0.86–1.09) 0.63
RE04 IFN-α 502 340 IFN-α, IL-2,5FU 504 351 1.02(0.89–1.16) 0.81 1.05(0.90–1.21) 0.55
ICON4 Plat. 378 220 Plat., TAX 361 199 0.81(0.69–0.95) 0.01 0.82(0.68–0.99) 0.04
RE01 MPA 176 167 IFN-α 174 155 0.68(0.54–0.84) <0.01 0.75(0.60–0.93) <0.01
aNumber of patients;
boverall survival events, that is deaths from any cause;
cprogression-free survival;
doverall survival.
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Figure 3 Kaplan–Meier plots of overall survival in four example trials, truncated at 5 years. The solid curve represents the control arm, and
the dashed curve represents the experimental arm in all four graphs.
Figure 3 shows the Kaplan–Meier plots of OS in the tri-
als, truncated at 5 years. There is a suspicion in Figure 3
that the survival curves of the two treatment groups
may cross in the RE04 trial, suggesting possible non-
proportional hazards. However, this was not conﬁrmed by
Grambsch–Therneau tests [15].
Design
We ‘redesigned’ all four example trials as two-stage TAMS
designs. Design parameters are given in Table 3 and are
based on values in the original trial protocols.We used the
nstage program [6] to compute the required number of
control arm events for the I outcome at stage 1 (interim
analysis for lack of eﬃcacy) and the D outcome at stage 2
(ﬁnal analysis of the deﬁnitive outcome). We took the D
outcome to be OS, and the I outcome to be OS or PFS in
separate analyses. We studied ﬁve one-sided signiﬁcance
levels α1 = (0.1, 0.2, 0.3, 0.4, 0.5) at stage 1, providing pro-
gressively earlier looks at the accumulating data. Stage 2
one-sided signiﬁcance level was α2 = 0.025 in all the
scenarios.
We ‘entered’ patients one by one in the same order as
they had presented in the original trial. Stage 1 analysis
was conducted when the target number of I events had
accrued (see Tables 4 and 5). Patients who had not entered
by the time of the stage 1 analysis were excluded from the
interim analysis. Trials were ‘stopped’ for lack of eﬃcacy
at stage 1 or continue recruitment to the ﬁnal analysis at
stage 2.
Table 3 Parameter values for trial reanalysis based on trial protocols
Design parameter Unsuccessful trials Successful trials
ICON3 RE04 ICON4 RE01
HR1I and HR
1
D 0.75 0.80 0.75 0.71
HR0I and HR
0
D 1.0 1.0 1.0 1.0
Power at stage 1 (ω1) 0.95 0.95 0.95 0.95
Power at stage 2 (ω2) 0.90 0.90 0.90 0.90
Overall power 0.855 0.855 0.855 0.855
Allocation ratio (control : experimental) 2:1 1:1 1:1 1:1
Median time to event for I outcome (months) 18 5.5 10 2.5
Median time to event for D outcome (months) 36 12 23 10
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Table 4 Simulation results for the trials which stop at stage 1
HR1D = 0.75 HR1D = 0.85
Design Under- %Stop Estimated HRD for trials stopped at stage 1 %Stop Estimated HRD for trials stopped at stage 1
lying at At interim point After follow-up at At interim point After follow-up
HRD stage 1 Mean (centilesa) %Bias Mean (centilesa) %Bias stage 1 Mean (centilesa) %Bias Mean (centilesa) %Bias
I outcome: OSb
1 1.10 70 1.19(1.01,1.52) 8 1.14(0.95,1.39) 4 83 1.13(1.01,1.33) 3 1.12(0.99,1.28) 2
1.00 50 1.14(1.00,1.42) 14 1.06(0.89,1.29) 6 50 1.08(1.00,1.24) 8 1.05(0.93,1.18) 5
0.88 22 1.10(1.00,1.32) 25 0.98(0.81,1.19) 11 10 1.04(1.00,1.16) 18 0.97(0.88,1.08) 10
0.75 4 1.06(1.00,1.23) 41 0.89(0.75,1.09) 19 0.2 1.03(1.00,1.12) 37 0.90(0.82,1.03) 20
2 1.10 95 1.11(0.93,1.36) 1 1.11(0.94,1.32) 1 99 1.10(0.98,1.24) 0 1.10(0.99,1.22) 0
1.00 80 1.04(0.92,1.25) 4 1.03(0.89,121) 3 80 1.02(0.95,1.14) 2 1.02(0.94,1.13) 2
0.88 37 0.98(0.91,1.13) 11 0.95(0.84,1.09) 8 13 0.98(0.95,1.05) 11 0.95(0.90,1.03) 8
0.75 5 0.95(0.91,1.05) 27 0.89(0.80,1.00) 19 0 − − − −
I outcome: PFSc
1 1.10 71 1.17(0.81,1.68) 6 1.11(0.92,1.38) 1 83 1.13(0.92,1.41) 3 1.11(0.98,1.29) 1
1.00 51 1.12(0.79,1.59) 12 1.05(0.87,1.28) 5 50 1.07(0.88,1.31) 7 1.04(0.91,1.19) 4
0.88 22 1.06(0.77,1.53) 20 0.96(0.80,1.17) 9 9 1.01(0.83,1.19) 15 0.95(0.84,1.09) 8
0.75 4 1.03(0.72,1.44) 37 0.88(0.71,1.04) 17 0 − −
2 1.10 96 1.11(0.85,1.44) 1 1.09(0.93,1.30) 1 99 1.10(0.95,1.28) 0 1.10(0.99,1.24) 0
1.00 79 1.04(0.81,1.34) 4 1.02(0.87,1.20) 2 79 1.02(0.90,1.16) 2 1.01(0.92,1.13) 1
0.88 39 0.97(0.76,1.23) 10 0.94(0.81,1.09) 7 13 0.96(0.85,1.07) 9 0.94(0.86,1.04) 7
0.75 4 0.92(0.74,1.13) 23 0.87(0.75,0.99) 16 0 − − − −
aThe 2.5th and 97.5th centiles of the estimated OS hazard ratios;
boverall survival;
cprogression-free survival.
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Table 5 Simulation results for the trials that reach the ﬁnal stage
Design Under- HR1D = 0.75 HR1D = 0.85
lying Estimated HRD for trials reached ﬁnal stage Estimated HRD for trials reached ﬁnal stage
HRD %Passa Mean (centilesb) %Bias %Passa Mean (centilesb) %Bias
I outcome: OSc
1 1.10 7 0.97(0.85,1.11) − 12 2 1.01(0.94,1.10) − 8
1.00 21 0.92(0.80,1.05) − 8 22 0.95(0.88,1.03) − 5
0.88 61 0.85(0.73,0.98) − 3 84 0.87(0.79,0.95) − 1
0.75 94 0.74(0.62,0.88) − 1 99.9 0.75(0.68,0.83) 0
2 1.10 1 0.90(0.78,1.01) − 18 0 − −
1.00 10 0.86(0.79,0.98) − 14 9 0.92(0.87,0.97) − 8
0.88 48 0.82(0.71,0.92) − 7 81 0.87(0.79,0.93) − 1
0.75 93 0.74(0.62,0.86) − 1 99.9 0.75(0.68,0.83) 0
I outcome: PFSd
1 1.10 7 1.01(0.86,1.17) − 8 2 1.04(0.96,1.13) − 5
1.00 22 0.94(0.80,1.09) − 6 23 0.97(0.88,1.05) − 3
0.88 61 0.85(0.73,0.99) − 3 84 0.87(0.79,0.96) − 1
0.75 93 0.74(0.62,0.88) − 1 99.8 0.75(0.68,0.83) 0
2 1.10 1 0.97(0.82,1.11) − 12 0 − −
1.00 9 0.91(0.79,1.05) − 9 9 0.95(0.86,1.03) − 5
0.88 47 0.84(0.72,0.98) − 5 82 0.87(0.79,0.95) − 1
0.75 93 0.74(0.62,0.88) − 1 100 0.75(0.68,0.83) 0
aPercentages of trials that pass interim stages 1 and 2 and continue accrual to the ﬁnal stage;
bthe 2.5th and 97.5th centiles of the estimated OS hazard ratios;
coverall survival;
dprogression-free survival.
Similar to our simulation studies, the number of repli-
cates was 5,000 in our bootstrap analysis of example
trials. In each replicate, the two types of selection bias (in
stopped ‘unsuccessful’ trials, and in ‘successful’ trials) were
investigated exactly as in the simulation study. Means of
OS log hazard ratios at stage 1 and at the planned end
of the trials are calculated separately. In all scenarios, we
report the results on the hazard ratio scale.
Results
Simulation results
The simulation results are summarized in Tables 4 and 5.
Table 4 gives the results for the trials that stop at stage 1.
The percentage of simulated trials in which the estimated
log hazard ratio exceeds the stage 1 threshold log(δ1) is
given. This is identiﬁed by ‘%Stop at stage 1’ in Table 4.
According to the TAMS design, recruitment to such tri-
als is ceased at the interim stage. Table 4 presents the
average treatment eﬀect on the D outcome, that is HRD,
together with the 2.5th and 97.5th centiles for the trials
that stopped at stage 1. We also followed up the individ-
uals in the same stopped trials to the original planned
end and computed the estimates of OS hazard ratios then.
Table 4 also shows the average of treatment eﬀect on theD
outcome at the end of the follow-up period in those trials
that stopped at stage 1 for lack of eﬃcacy.
The average treatment eﬀect for trials stopped at stage
1 is biased in all experimental conditions. This bias
increases as the underlying hazard ratio moves from 1.1
to 0.75. However, the smaller the underlying hazard ratio,
the less likely a trial is to stop at stage 1 – see %Stop in
Table 4. The bias is smaller in Design 2 because the lower
signiﬁcance level in stage 1 increases the required number
of events and makes the data more mature at this point
than in Design 1.
The results in Table 4 indicate that the true (underlying)
hazard ratio is overestimated at stage 1 in all scenarios. A
key ﬁnding is that when follow-up of patients in stopped
trials is continued to the planned end of the ﬁnal stage, the
bias is much reduced. For instance, in Design 1 when the
target hazard ratioHR1D = 0.75 with an underlyingHRD of
1.1 – the ﬁrst row in the left panel of Table 4 – the percent-
age bias in the average treatment eﬀect for the trials which
stopped at stage 1 is 8% – that is 100× (1.19− 1.10)/1.10.
This decreases to 4% after follow-up to the planned end
of the trial. In all cases, after follow-up of patients to the
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original planned end of the trial, the bias is generally min-
imal (mostly less than 6%) if the underlying eﬀect is in the
direction of null hypothesis. In the dropped trials, the bias
is slightly smaller when the intermediate outcome, that is
PFS, is used for selection at the interim stages.
We also calculated the average of treatment eﬀect on
the D outcome for trials that stopped at either of the two
interim stages (data not shown). The selection bias is very
similar to the corresponding values in Table 4 when the I
outcome is PFS, and the bias becomes smaller when the I
outcome is OS.
Table 5 presents the average treatment eﬀect on the
D outcome at the ﬁnal stage for the trials that pass
both interim stages. The bias at the ﬁnal stage is gener-
ally smaller when the target hazard ratio HR1D = 0.85,
compared with the corresponding values when target haz-
ard ratio HR1D = 0.75. However, the main result from
this table is that in the trials that reach the ﬁnal stage,
the selection bias in the average treatment eﬀect is very
small provided that the underlying eﬀect is closer to the
alternative hypothesis. There is some bias in the average
treatment eﬀect when the underlying eﬀect is closer to the
null hypothesis, but in such scenarios the chance that the
research arm is dropped at the interim stages is large – see
%Pass in Table 5.
Bootstrap results
The results of the bootstrap reanalyses of the trials show-
ing evidence of an eﬀect (ICON3 and RE04) are sum-
marized in Tables 6 and 7. Table 6 shows the average
treatment eﬀect on the D outcome for the trials that
stopped at stage 1 together with their corresponding 2.5th
and 97.5th centiles. For the left side of the table OS was
used at the interim stage to select trials. On the right PFS
was used at the interim stage to select trials. The number
of replications was 5,000 in all experimental conditions.
Results in Table 6 indicates that bias is present in the tri-
als that did not pass stage 1. For example, the original OS
hazard ratio in ICON3 is 0.97 (95% bootstrap CI: 0.87–
1.09). For this trial, 1907 (38%) of the 5,000 replicated
trials stopped at stage 1 when I = D and α1 = 0.50 – the
ﬁrst line in the left panel of Table 6. The average treatment
eﬀect for the stopped trials is 1.12. But, after the follow-up,
the average treatment eﬀect reduces to 0.96 and the selec-
tion bias nearly disappears. In general, the bias decreases
with decreasing α1 and δ1. This is due, as before, to the
increasing amount of information (that is patient events)
that is required at the ﬁrst interim for these design param-
eters. In all example trials, the bias is very small after the
follow-up if the stage 1 signiﬁcance level α1 is chosen to
be smaller than 0.40.
Furthermore, for the scenarios presented in Table 6, we
also computed the average treatment eﬀect on the D out-
come at the ﬁnal stage for the trials which passed the
interim stage. The results, presented in Table 7, show that
the bias in the average treatment eﬀect in those trials
is very small in most scenarios. Results for RE04 show
some bias in some scenarios, but the chance of passing the
interim stage is relatively small in those conditions – see
%Pass.
The results of the bootstrap reanalyses of the ‘successful’
trials (ICON4 and RE01) are summarized in Tables 8 and
9. Table 8 shows the results for the trials that reach the
ﬁnal stage. For ICON4, 99% of trials reached the ﬁnal stage
when α1 = 0.5 and the I outcome was OS. In contrast to
the unsuccessful trials, the results for the successful trials
show that there is almost no bias in the estimated hazard
ratio on OS at the ﬁnal stage.
In ICON4 and RE01, we also computed the average
treatment eﬀect for the stopped trials at the interim stage.
The results in Table 9 reaﬃrm that follow-up decreases
the amount of bias in most scenarios. It should be noted
that unlike our simulation studies where (under the pro-
portional hazards assumption) the treatment eﬀect is
assumed to be constant over time, in real trials the eﬀect
may not be constant over time. With real trial data we will
not know whether the underlying process that created it
satisﬁes the PH assumption or not. Even if the underly-
ing data generating model did satisfy the PH assumption,
it is still possible for a single realization of this process
(that is one trial’s worth of data) to empirically depart
from PH. In fact, as Figure 4 demonstrates the estimate
of treatment eﬀect in ICON4 ﬂuctuates (in some parts
markedly) early in the course of the trials. The ﬁnal over-
all estimate for HRD is 0.82 - red dashed line. However,
the mean bootstrapped estimate – that is the means of
OS hazard ratios for all 5,000 replicated trials – changes
from 0.83, 0.74, 0.70, 0.73 to 0.76 when α1 is 0.5, 0.4, 0.3,
0.2 and 0.1, respectively. The corresponding time points of
interim analysis for these α1 values are 2.4, 2.9, 3.4, 4.1 and
4.9 years after the start of the trial, respectively. This is the
reason for the (relatively large) bias in the average eﬀect
of stopped trials in some scenarios presented in Table 9.
However, it can be argued that a larger bias in these situ-
ations is not so important since we are not claiming that
the experimental treatment is eﬀective.
Discussion
In this paper, we have assessed the validity of the estimates
of treatment eﬀects resulting from a TAMS design, with
a speciﬁc focus on bias. By deﬁning the ‘selection bias’
in selected and dropped treatments, we have quantiﬁed
its likely magnitude via a simulation study and bootstrap
reanalysis of existing trials. Our results highlight that the
amount of selection bias is generally small and its degree
depends on the design parameters and the unknown true
(underlying) eﬀect values.
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Table 6 Bootstrap results for the stopped trials based on ICON3 and RE04 in a two-stage design
I and D outcomes are OSa I outcome is PFSb, D outcome is OSa
%Stop Estimated HRD for trials stopped at stage 1 %Stop Estimated HRD for trials stopped at stage 1
at At interim point After follow-up at At interim point After follow-up
α1
c δ1
d e1e stage 1 Mean (centiles) %Bias Mean (centile) %Bias e1e stage 1 Mean (centiles) %Bias Mean (centiles) %Bias
a) ICON3 – HRD (95% bootstrap CI): 0.97(0.87–1.09)
0.50 1.00 118 38 1.12(1.00,1.40) 15 0.96(0.84,1.10) 1 116 55 1.27(0.88,1.83) 31 0.93(0.79,1.10) − 4
0.40 0.97 153 55 1.08(0.97,1.31) 11 0.98(0.86,1.11) 1 152 52 1.15(0.83,1.56) 19 0.95(0.81,1.10) − 2
0.30 0.94 195 52 1.03(0.94,1.22) 6 0.98(0.87,1.10) 1 194 33 1.09(0.81,1.45) 12 0.97(0.85,1.11) 0
0.20 0.91 252 42 0.99(0.91,1.15) 2 0.99(0.89,1.10) 2 250 12 1.16(0.89,1.46) 20 1.00(0.89,1.12) 3
0.10 0.89 342 44 0.95(0.89,1.08) − 2 0.99(0.90,1.10) 2 339 29 1.06(0.86,1.31) 9 1.00(0.90,1.12) 3
b) RE04 – HRD (95% bootstrap CI): 1.05(0.90–1.21)
0.50 1.00 118 34 1.09(1.00,1.27) 4 1.10(0.95,1.26) 5 116 33 0.92(0.66,1.32) − 12 1.07(0.89,1.30) 2
0.40 0.97 155 36 1.06(0.97,1.26) 1 1.09(0.96,1.24) 4 152 67 0.89(0.67,1.19) − 15 1.02(0.86,1.23) −3
0.30 0.95 199 71 1.05(0.95,1.23) 0 1.05(0.93,1.20) 0 196 79 0.95(0.74,1.23) − 10 1.05(0.90,1.24) 0
0.20 0.93 259 84 1.05(0.95,1.23) 0 1.06(0.94,1.21) 1 255 73 0.96(0.78,1.19) − 9 1.04(0.90,1.21) − 1
0.10 0.91 355 79 1.05(0.92,1.26) 0 1.06(0.92,1.22) 1 351 97 1.02(0.86,1.22) − 3 1.03(0.89,1.20) − 2
aOverall survival;
bprogression-free survival;
cone-sided signiﬁcance level at stage 1;
dpredeﬁned threshold at stage 1;
ecumulative number of control arm events required at end of stage 1.
Choodari-Oskooei et al. Trials 2013, 14:23 Page 11 of 15
http://www.trialsjournal.com/content/14/1/23
Table 7 Bootstrap results for the trials that reach the ﬁnal stage based on ICON3 and RE04
I and D outcomes are OSa I outcome is PFSb, D outcome is OSa
Estimated HRD for trials reached ﬁnal stage Estimated HRD for trials reached ﬁnal stage
α1
c δ1
d e1e %Passf Mean (centiles) %Bias e1e %Passf Mean (centiles) %Bias
a) ICON3 – HRD (95% bootstrap CI): 0.97(0.87–01.09)
0.50 1.00 118 62 0.96(0.86,1.07) − 1 116 45 0.96(0.85,1.07) − 1
0.40 0.97 153 45 0.97(0.85,1.06) 0 152 48 0.95(0.85,1.07) − 2
0.30 0.94 195 48 0.95(0.85,1.06) − 2 194 67 0.96(0.86,1.07) − 1
0.20 0.91 252 58 0.95(0.85,1.06) − 2 250 88 0.97(0.86,1.08) 0
0.10 0.89 342 56 0.95(0.85,1.05) − 2 339 71 0.96(0.86,1.06) − 1
b) RE04 – HRD (95% bootstrap CI): 1.05(0.90–1.21)
0.50 1.00 118 66 1.02(0.89,1.16) - 3 116 67 1.03(0.89,1.19) − 2
0.40 0.97 155 64 1.02(0.89,1.16) - 3 152 33 1.01(0.88,1.16) −4
0.30 0.95 199 29 0.98(0.87,1.10) −7 196 21 0.99(0.87,1.13) −6
0.20 0.93 259 16 0.95(0.85,1.04) −10 255 27 0.99(0.87,1.13) −6
0.10 0.91 355 21 0.97(0.86,1.08) −8 351 3 0.94(0.80,1.07) −10
aOverall survival events;
bprogression-free survival;
cone-sided signiﬁcance level at stage 1;
dpredeﬁned threshold at stage 1;
ecumulative number of control arm events required at end of stage 1;
fpercentages of trials that pass the interim stage and continue accrual to the ﬁnal stage.
Table 8 Bootstrap results for trials that reached the ﬁnal stage based on ICON4 and RE01
I and D outcomes are OSa I outcome is PFSb, D outcome is OSa
Estimated HRD for trials reached ﬁnal stage Estimated HRD for trials reached ﬁnal stage
α1
c δ1
d e1e %Passf Mean (centiles) %Bias e1e %Passf Mean (centiles) %Bias
a) ICON4 – HRD (95% bootstrap CI): 0.82(0.67,0.99)
0.50 1.00 75 99 0.82(0.67,0.98) 0 75 99 0.82(0.67,0.99) 0
0.40 0.96 98 97 0.82(0.67,0.97) 0 97 99 0.82(0.67,0.99) 0
0.30 0.94 126 96 0.82(0.67,0.97) 0 125 98 0.82(0.67,0.98) 0
0.20 0.91 163 92 0.81(0.67,0.94) − 1 162 96 0.81(0.67,0.97) 1
0.10 0.89 222 86 0.81(0.67,0.94) − 1 221 89 0.81(0.67,0.96) 1
b) RE01 – HRD (95% bootstrap CI): 0.75(0.60,0.93)
0.50 1.00 51 87 0.74(0.60,0.90) −1 49 93 0.75(0.60,0.92) 0
0.40 0.96 66 89 0.74(0.60,0.90) −1 64 92 0.75(0.60,0.92) 0
0.30 0.92 85 94 0.74(0.60,0.90) −1 83 96 0.75(0.60,0.92) 0
0.20 0.89 110 99 0.71(0.59,0.80) − 5 108 99 0.75(0.60,0.92) 0
0.10 0.86 150 89 0.73(0.60,0.86) − 3 148 98 0.75(0.60,0.92) 0
aOverall survival;
bprogression-free survival;
cone-sided signiﬁcance level at stage 1;
dpredeﬁned threshold at stage 1;
ecumulative number of control arm events required at end of stage 1;
fpercentages of trials that pass the interim stage and continue accrual to the ﬁnal stage.
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Table 9 Bootstrap results for the stopped trials based on ICON4 and RE01 in a two-stage design
I and D outcomes are OSa I outcome is PFSb, D outcome is OSa
Estimated HRD for trials stopped at stage 1 Estimated HRD for trials stopped at stage 1
% At interim point After follow-up At interim point After follow-up
α1
c δ1
d e1e %Stop Mean (centiles) %Bias Mean (centiles) %Bias e1e %Stop Mean (centiles) %Bias Mean (centiles) %Bias
a) ICON4 – HRD (95% bootstrap CI): 0.82(0.67, 0.99)
0.50 1.00 75 1 1.05(1.00,1.20) 28 0.98(0.81,1.18) 20 75 1 1.17(0.80,1.66) 43 0.91(0.73,1.16) 11
0.40 0.96 98 3 1.01(0.97,1.18) 23 0.99(0.86,1.21) 21 97 1 0.99(0.71,1.31) 21 0.94(0.76,1.15) 15
0.30 0.94 126 4 0.98(0.94,1.12) 20 1.01(0.88,1.18) 23 125 2 0.87(0.66,1.12) 6 0.97(0.84,1.18) 18
0.20 0.91 163 8 0.96(0.91,1.09) 17 0.97(0.88,1.10) 18 162 5 0.89(0.70,1.12) 9 0.96(0.82,1.13) 17
0.10 0.89 222 14 0.99(0.89,1.55) 21 0.91(0.68,1.10) 11 221 12 0.86(0.70,1.05) 5 0.96(0.82,1.13) 17
b) RE01 – HRD (95% bootstrap CI): 0.75(0.60,0.93)
0.50 1.00 51 13 1.10(1.00,1.37) 47 0.96(0.76,1.21) 28 49 7 1.21(0.80,1.80) 61 1.11(0.77,1.56) 48
0.40 0.96 66 11 1.04(0.96,1.27) 39 0.91(0.74,1.16) 21 64 8 1.06(0.76,1.50) 41 0.97(0.69,1.37) 29
0.30 0.92 85 6 0.99(0.93,1.14) 32 0.92(0.77,1.14) 23 83 4 1.02(0.77,1.31) 36 0.91(0.71,1.22) 21
0.20 0.89 110 6 0.95(0.89,1.09) 27 0.90(0.77,1.06) 20 108 1 0.97(0.68,1.24) 29 0.93(0.69,1.23) 24
0.10 0.86 150 11 0.91(0.86,1.04) 21 0.88(0.72,0.95) 17 148 2 0.90(0.76,1.10) 20 0.86(0.73,1.05) 15
aOverall survival;
bprogression-free survival;
cone-sided signiﬁcance level at stage 1;
dpredeﬁned threshold at stage 1;
ecumulative number of control arm events required at end of stage 1.
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Figure 4 Development of overall survival log hazard ratio over time in ICON4 trial. Gray curves are the corresponding 95% CIs. The dashed
horizontal line shows the overall (underlying) eﬀect. The vertical dotted lines specify the interim analysis time points (see text for calendar time)
where stage 1 analysis is carried out based on diﬀerent design signiﬁcance levels α1 – the I outcome is PFS.
In the TAMS design, the bias generally tends to be larger
when selecting ‘early’, that is, when the decision is based
on a relatively small number of events. The results also
show that, as pointed out by Royston et al. [5], under
some assumptions bias in treatment eﬀects on the deﬁni-
tive outcome can be markedly reduced by following all
patients up to the planned end of the trial and perform-
ing analyses then, irrespective of whether recruitment
was stopped early for lack of beneﬁt. (Follow-up can also
help in capturing the relevant information on safety end-
points.) Of course, it can be argued that by deﬁnition for
arms that have stopped early a claim that the experimen-
tal treatment is better than the control is not made so the
fact that treatment eﬀect is biased is less important.
In our analyses, by choosing diﬀerent signiﬁcance lev-
els for the ﬁrst interim stage we also explored the timing
of the ﬁrst interim stage analysis at which the bias will be
small. Our investigations suggest that the bias will be min-
imal, if the ﬁrst interim stage is placed at a signiﬁcance
level of 0.3 or less. As a trade-oﬀ between the amount of
bias and eﬃciency, we suggest that the ﬁrst interim stage
to be deﬁned by a signiﬁcance level between 0.2 and 0.3.
This suggestion accords with the recommendations made
by Barthel et al. [14]. However, this is only a practical rec-
ommendation with respect to bias and does not reﬂect
an optimal design which could be obtained from a sim-
ulation study or theoretical calculation. Furthermore, we
have shown that the bias in the treatment eﬀect would
become negligible if the TAMS trials were powered at
small eﬀect sizes investigating treatments with true large
eﬀect sizes. This, however, would in practice increase the
number of events required and so the cost and duration of
the trial. Finally, our simulation results showed that using
an intermediate outcome measure reduces the selection
bias in the estimates of treatment eﬀects in both selected
and dropped arms – provided that the chosen interme-
diate outcome measure satisﬁes the conditions set out by
Royston et al. [1].
However, we emphasize that the selection bias in the
estimate of treatment eﬀect of trials that reach the ﬁnal
stage is a more major consideration than that in stopped
trials. An eﬀective experimental arm is very likely to reach
the ﬁnal stage of a TAMS trial, and the results of such
trials are more likely to be adopted into clinical practice.
Our empirical studies showed that the size of selection
bias for the trials that reach the ﬁnal stage is generally
small. In fact, the bias is negligible if the experimental
arm is truly eﬀective.
For a dropped treatment arm, the estimate of the treat-
ment eﬀect is generally on the extremes of its sampling
distribution – see Figure 2 and also Figure 2 in [8]. The
estimate, as suggested by Goodman [16] and Freidlin
and Korn [17], is generally on a random high (or low,
depending on the direction of eﬃcacy). Freidlin and
Korn [17] argued that one should take this into consid-
eration, and compare the average eﬀect in the dropped
arm with the average eﬀect of a ‘similar’ ﬁxed sample
size trial, which is on the random high – see [16,17] for
their deﬁnition of ‘similar’. Their proposed ﬁxed sample
size comparator is hypothetical and quite complicated.
In our simulation studies, we also compared the average
eﬀect in the dropped arm of a TAMS design with their
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proposed comparator (results not shown). Our ﬁndings
showed that after the follow-up the average eﬀect in
the dropped arm is almost identical to their proposed
comparator. Freidlin and Korn [17] concluded that in
trials with a well-designed interim-monitoring plan, the
selection bias is negligible if one compares the average
eﬀect in the dropped arms to their ﬁxed sample size
comparator. Therefore, our conclusions about the TAMS
designs, although in a slightly diﬀerent context, agree in
principle with the ﬁndings of Freidlin and Korn [17]’s
investigations.
Several unbiased estimators of the treatment eﬀect have
been proposed to correct for bias inherent in two-stage
designs of the TAMS type, although they were originally
developed in a diﬀerent context for trials with continu-
ous, conditionally normal outcome variables. Cohen and
Sackrowitz [18] and Bowden and Glimm [19]’s formula
can be applied to the deﬁnitive endpoint at the end of
a two-stage trial when the deﬁnitive endpoint has been
used to decide on continuing/dropping the research arm
at the interim analysis. Sill and Sampson [20] extended
Cohen and Sackrowitz’s unbiased (UMVCUE) estimator
to the case where the interim decision is based on an
intermediate outcome. We chose not to include a thor-
ough comparison of these bias-adjusted estimators in our
paper for several reasons. First and foremost, we are
dealing with (censored) time-to-event data and Sill and
Sampson’s [20] formulae do not naturally extend to such
a case. Second, in our situation the bias in the stan-
dard treatment eﬀect estimates at the end of the trial
was shown to be small. Third, the aforementioned for-
mulae are presently only available for two-stage trials
and are inapplicable to TAMS designs with more than
two stages. This is a topic for further research. Finally,
even if an unbiased estimator was available, it might
not be preferred to the slightly biased standard (ML)
estimator because its mean square error is likely to be
larger [20,21].
Conclusions
Our empirical studies show that the estimated treatment
eﬀect on the deﬁnitive outcome has a small bias at the time
of ceasing recruitment to an arm. However, if follow-up is
continued to the planned end of the trial, even this small
bias decreases markedly. Our results also suggest that in
trials with a truly eﬃcacious experimental arm that con-
tinue to the planned end, the bias is very small and of no
practical importance.
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